Philippe Aftimos, MD · @aftimosp · X·· 1 天前评分70
正文 · 机器翻译
T-DXd 在 HER2-low 和 ultra-low HR+/HER2- MBC 中获批，此前其在关键性 ph3 试验中改善了治疗结局。
❓T-DXd 在 HER2-low/HR+ 早期乳腺癌中的作用？
TALENT 的最终结果于今天在 #ESMO26 上公布，@breastDoktor 对其进行了描述与点评。
#ESMOAmbassadors 👇
183 浏览 · 2 赞 · 0 转发 · 1 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org#ESMO26: Final results from the TALENT #ClinicalTrial show low pathological complete response rates with the antibody–drug conjugate (#ADC) trastuzumab deruxtecan in HR-positive, HER2-low #EarlyBreastCancer, as discussed by @breastDoktor #InsightsbyESMO ➡️ https://ow.ly/ZBwi50ZZXLm在 X 查看被引用的帖子
帖内回复
- Philippe Aftimos, MD @aftimosp
Results also here #ESMO26 #ESMOAmbassadors
来源：Philippe Aftimos, MD · x.com